{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:11:59Z","timestamp":1790871119227,"version":"4.1.0"},"reference-count":110,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T00:00:00Z","timestamp":1557360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Hepatitis B virus (HBV) cannot be completely eliminated from infected hepatocytes due to the existence of intrahepatic covalently closed circular DNA (cccDNA). Serological biomarkers reflect intrahepatic viral replicative activity as non-invasive alternatives to liver biopsy. Hepatitis B core-related antigen (HBcrAg) is a novel biomarker that has an important role in chronic hepatitis B (CHB), because it correlates with serum HBV DNA and intrahepatic cccDNA. In clinical cases with undetectable serum HBV DNA or loss of HBsAg, HBcrAg still can be detected and the decrease in HBcrAg levels is significantly associated with promising outcomes for CHB patients. HBcrAg can predict spontaneous or treatment-induced hepatitis B envelope antigen (HBeAg) seroconversion, persistent responses before and after cessation of nucleos(t)ide analogues, potential HBV reactivation, HBV reinfection after liver transplantation, and risk of hepatocellular carcinoma progression or recurrence. In this review, the clinical applications of HBcrAg in CHB patients based on its virological features are described. Furthermore, new potential therapeutic anti-HBV agents that affect intrahepatic cccDNA are under development, and the monitoring of HBcrAg might be useful to judge therapeutic effects. In conclusion, HBcrAg might be a suitable surrogate marker beyond other HBV markers to predict the disease progression and treatment responses of CHB patients.<\/jats:p>","DOI":"10.3390\/genes10050357","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T11:22:35Z","timestamp":1557400955000},"page":"357","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["The Role of Hepatitis B Core-Related Antigen"],"prefix":"10.3390","volume":"10","author":[{"given":"Takako","family":"Inoue","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Nagoya City University Hospital, Nagoya 467-8602, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Nagoya City University Hospital, Nagoya 467-8602, Japan"},{"name":"Department of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.bpg.2015.09.011","article-title":"Hepatitis B vaccination and prevention of hepatocellular carcinoma","volume":"29","author":"Kao","year":"2015","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_2","unstructured":"World Health Organization (2019, April 01). World Health Organization Factsheets for Chronic Hepatitis B. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/0003-4819-147-1-200707030-00010","article-title":"The natural history and treatment of chronic hepatitis B: A critical evaluation of standard treatment criteria and end points","volume":"147","author":"Lai","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1473-3099(02)00315-8","article-title":"Global control of hepatitis B virus infection","volume":"2","author":"Kao","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.15698\/mic2016.09.527","article-title":"Hepatitis B Virus and Its Sexually Transmitted Infection\u2014An Update","volume":"3","author":"Inoue","year":"2016","journal-title":"Microb. Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2008.07.014","article-title":"Statements from the Taormina expert meeting on occult hepatitis B virus infection","volume":"49","author":"Raimondo","year":"2008","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/jhep.2001.25172","article-title":"Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely \u201coccult\u201d?","volume":"34","author":"Brechot","year":"2001","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jhep.2005.02.005","article-title":"The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma","volume":"42","author":"Roberts","year":"2005","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"(2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jfma.2015.06.003","article-title":"Perspectives and control of hepatitis B virus infection in Taiwan","volume":"114","author":"Lin","year":"2015","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s12072-015-9698-x","article-title":"Looking into the crystal ball: Biomarkers for outcomes of HBV infection","volume":"10","author":"Yang","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.26041","article-title":"Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads","volume":"57","author":"Tseng","year":"2013","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1053\/j.gastro.2008.07.008","article-title":"HBsAg Seroclearance in chronic hepatitis B in Asian patients: Replicative level and risk of hepatocellular carcinoma","volume":"135","author":"Yuen","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1053\/j.gastro.2010.01.042","article-title":"Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death","volume":"138","author":"Chen","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/apt.13634","article-title":"Systematic review with meta-analysis: Development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance","volume":"43","author":"Liu","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2014.11.031","article-title":"Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: A need for surveillance","volume":"62","author":"Kim","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/jvh.12993","article-title":"New viral biomarkers for Hepatitis B: Are we able to change practice?","volume":"25","author":"Maasoumy","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mak, L.Y., Seto, W.K., Fung, J., and Yuen, M.F. (2019). New Biomarkers of Chronic Hepatitis B. Gut Liver.","DOI":"10.5009\/gnl18425"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/JCM.00726-13","article-title":"Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance","volume":"51","author":"Shinkai","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/liv.13349","article-title":"Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay","volume":"37","author":"Shinkai","year":"2017","journal-title":"Liver Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/1469-0691.12739","article-title":"Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B","volume":"20","author":"Seto","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e05570","DOI":"10.7554\/eLife.05570","article-title":"Correction: Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"3","author":"Yan","year":"2014","journal-title":"eLife"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"eLife"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Yang, H.C., and Kao, J.H. (2014). Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: Molecular mechanisms and clinical significance. Emerg. Microbes Infect., 3.","DOI":"10.1038\/emi.2014.64"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gerlich, W.H. (2013). Medical virology of hepatitis B: How it began and where we are now. Virol. J., 10.","DOI":"10.1186\/1743-422X-10-239"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/MMBR.64.1.51-68.2000","article-title":"Hepatitis B virus biology","volume":"64","author":"Seeger","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(86)90602-1","article-title":"Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells","volume":"47","author":"Tuttleman","year":"1986","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/JCM.40.2.439-445.2002","article-title":"Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load","volume":"40","author":"Kimura","year":"2002","journal-title":"J. Clin. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2893.2003.00437.x","article-title":"Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment","volume":"10","author":"Rokuhara","year":"2003","journal-title":"J. Viral Hepat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jmv.21339","article-title":"Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients","volume":"81","author":"Suzuki","year":"2009","journal-title":"J. Med. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"606.e601","DOI":"10.1016\/j.cmi.2015.02.010","article-title":"Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D","volume":"21","author":"Maasoumy","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"21713","DOI":"10.1074\/jbc.M501564200","article-title":"Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain","volume":"280","author":"Kimura","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Hadziyannis, E., and Laras, A. (2018). Viral Biomarkers in Chronic HBeAg Negative HBV Infection. Genes, 9.","DOI":"10.3390\/genes9100469"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3350\/cmh.2016.0069","article-title":"New perspectives of biomarkers for the management of chronic hepatitis B","volume":"22","author":"Lin","year":"2016","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/apt.14376","article-title":"Review article: Hepatitis B core-related antigen (HBcrAg): An emerging marker for chronic hepatitis B virus infection","volume":"47","author":"Mak","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/JCM.00366-07","article-title":"Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection","volume":"45","author":"Wong","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1111\/j.1440-1746.2005.04087.x","article-title":"Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection","volume":"20","author":"Rokuhara","year":"2005","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/liv.13346","article-title":"Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA","volume":"37","author":"Wong","year":"2017","journal-title":"Liver Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.20353","article-title":"Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients","volume":"40","author":"Wong","year":"2004","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Chen, E.Q., Feng, S., Wang, M.L., Liang, L.B., Zhou, L.Y., Du, L.Y., Yan, L.B., Tao, C.M., and Tang, H. (2017). Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-00111-0"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1478-3231.2005.01200.x","article-title":"Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance","volume":"26","author":"Tanaka","year":"2006","journal-title":"Liver Int."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wang, L., Cao, X., Wang, Z., Gao, Y., Deng, J., Liu, X., and Zhuang, H. (2019). Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients. J. Clin. Microbiol., 57.","DOI":"10.1128\/JCM.01303-18"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hasegawa, K., Nishikawa, H., Enomoto, H., Iwata, Y., Sakai, Y., Ikeda, N., Takashima, T., Aizawa, N., Takata, R., and Yoh, K. (2018). Proposed model for the prediction of intrahepatic covalently closed circular DNA level in patients with chronic hepatitis B. Hepatol. Res.","DOI":"10.1111\/hepr.13280"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection--natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/v1020185","article-title":"HBV life cycle: Entry and morphogenesis","volume":"1","author":"Schadler","year":"2009","journal-title":"Viruses"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4254\/wjh.v10.i9.603","article-title":"Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA","volume":"10","author":"Liu","year":"2018","journal-title":"World J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bpg.2017.04.009","article-title":"What is new on HBsAg and other diagnostic markers in HBV infection?","volume":"31","author":"Maasoumy","year":"2017","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Liu, S., Zhou, B., Valdes, J.D., Sun, J., and Guo, H. (2018). Serum HBV RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection. Hepatology.","DOI":"10.1002\/hep.30325"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Liao, H., Liu, Y., Li, X., Wang, J., Chen, X., Zou, J., Li, Q., Liu, L., Wang, J., and Huang, B. (2018). Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside\/nucleotide analogue therapy. Antivir. Ther.","DOI":"10.3851\/IMP3314"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jcv.2017.12.016","article-title":"Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals","volume":"99\u2013100","author":"Huang","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/jvh.13061","article-title":"Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA","volume":"26","author":"Chen","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Suzuki, Y., Maekawa, S., Komatsu, N., Sato, M., Tatsumi, A., Miura, M., Matsuda, S., Muraoka, M., Nakakuki, N., and Amemiya, F. (2019). HBV preS deletion mapping using deep sequencing demonstrates a unique association with viral markers. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0212559"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jvh.13054","article-title":"Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B","volume":"26","author":"Loggi","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/jmv.20505","article-title":"Patients with and without loss of hepatitis B virus DNA after hepatitis B e antigen seroconversion have different virological characteristics","volume":"78","author":"Misawa","year":"2006","journal-title":"J. Med. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Testoni, B., Lebosse, F., Scholtes, C., Berby, F., Miaglia, C., Subic, M., Loglio, A., Facchetti, F., Lampertico, P., and Levrero, M. (2018). Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J. Hepatol.","DOI":"10.1016\/j.jhep.2018.11.030"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jviromet.2016.05.016","article-title":"Measurement of the hepatitis B core-related antigen is valuable for predicting the pathological status of liver tissues in chronic hepatitis B patients","volume":"235","author":"Zhang","year":"2016","journal-title":"J. Virol. Methods"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s12072-012-9354-7","article-title":"Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay","volume":"7","author":"Seto","year":"2012","journal-title":"Hepatol. Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/liv.13046","article-title":"Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B","volume":"36","author":"Chuaypen","year":"2016","journal-title":"Liver Int."},{"key":"ref_63","unstructured":"(2014). JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol. Res., 44, 1\u201358."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","article-title":"Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B","volume":"66","author":"Lai","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350801300106","article-title":"Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication","volume":"13","author":"Lutgehetmann","year":"2008","journal-title":"Antivir. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.4103\/0366-6999.189904","article-title":"HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b","volume":"129","author":"Ma","year":"2016","journal-title":"Chin. Med. J. (Engl.)"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/hepr.12811","article-title":"Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-alpha","volume":"47","author":"Caviglia","year":"2017","journal-title":"Hepatol. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/hepr.12488","article-title":"Factors associated with the effect of interferon-alpha sequential therapy in order to discontinue nucleoside\/nucleotide analog treatment in patients with chronic hepatitis B","volume":"45","author":"Matsumoto","year":"2015","journal-title":"Hepatol. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jvh.12565","article-title":"Baseline HBsAg and HBcrAg titres allow peginterferon-based \u2019precision medicine\u2019 in HBeAg-negative chronic hepatitis B patients","volume":"23","author":"Lapalus","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jvh.12889","article-title":"HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues","volume":"25","author":"Wang","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wang, M.L., Deng, R., Chen, E.Q., Tao, C.M., Liao, J., Zhou, T.Y., Wang, J., and Tang, H. (2018). Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy. Clin. Res. Hepatol. Gastroenterol.","DOI":"10.1016\/j.clinre.2018.10.020"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00535-015-1153-1","article-title":"Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients","volume":"51","author":"Jung","year":"2016","journal-title":"J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1872-034X.2007.00094.x","article-title":"Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy","volume":"37","author":"Matsumoto","year":"2007","journal-title":"Hepatol. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.hepres.2006.08.005","article-title":"Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection","volume":"36","author":"Shinkai","year":"2006","journal-title":"Hepatol. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/apt.15058","article-title":"Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk","volume":"49","author":"Hsu","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/apt.15108","article-title":"Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues","volume":"49","author":"Hosaka","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jhep.2012.10.025","article-title":"Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: A propensity score analysis","volume":"58","author":"Kumada","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/infdis\/jiv572","article-title":"Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma","volume":"213","author":"Honda","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jhep.2016.03.013","article-title":"HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics","volume":"65","author":"Tada","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cca.2018.07.027","article-title":"Clinical evaluation of hepatitis B core-related antigen in chronic hepatitis B and hepatocellular carcinoma patients","volume":"486","author":"Chen","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.3748\/wjg.v19.i39.6515","article-title":"Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy","volume":"19","author":"Wong","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/jvh.12688","article-title":"Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy","volume":"24","author":"Cheung","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.13277","article-title":"Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma","volume":"49","author":"Suzuki","year":"2019","journal-title":"Hepatol. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/hep.28266","article-title":"Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation","volume":"63","author":"Lee","year":"2016","journal-title":"Hepatology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamasurg.2013.4648","article-title":"Prediction of hepatocellular carcinoma recurrence in patients with low hepatitis B Virus DNA levels and high preoperative hepatitis B surface antigen levels","volume":"149","author":"Huang","year":"2014","journal-title":"JAMA Surgery"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/jgh.12917","article-title":"Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: A systematic review and meta-regression analysis","volume":"30","author":"Zhou","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s00535-016-1240-y","article-title":"The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients","volume":"52","author":"Urabe","year":"2017","journal-title":"J. Gastroenterol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/ajg.2016.436","article-title":"Association of Hepatitis B Core-Related Antigen with Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy","volume":"111","author":"Seto","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-6143.2003.00063.x","article-title":"Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era","volume":"3","author":"Papatheodoridis","year":"2003","journal-title":"Am. J. Transplant."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.transproceed.2004.02.025","article-title":"Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation","volume":"36","author":"Ferretti","year":"2004","journal-title":"Transplant. Proc."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/jgh.12182","article-title":"Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation","volume":"28","author":"Matsuzaki","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2169\/internalmedicine.48.2000","article-title":"The significance of enzyme immunoassay for the assessment of hepatitis B virus core-related antigen following liver transplantation","volume":"48","author":"Fujimoto","year":"2009","journal-title":"Intern. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s12072-011-9265-z","article-title":"Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis","volume":"5","author":"Yasunaka","year":"2011","journal-title":"Hepatol. Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1586\/17474124.2016.1145547","article-title":"Hepatitis B: Treatment choice and monitoring for response and resistance","volume":"10","author":"Liu","year":"2016","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.antiviral.2018.07.011","article-title":"Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro","volume":"158","author":"Corcuera","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.antiviral.2017.06.016","article-title":"Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype A-H clinical isolates and core site-directed mutants in vitro","volume":"144","author":"Berke","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/mt.2013.31","article-title":"Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection","volume":"21","author":"Wooddell","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1089\/nat.2012.0389","article-title":"Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo","volume":"22","author":"Wong","year":"2012","journal-title":"Nucl. Acid Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2015.06.019","article-title":"Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent","volume":"121","author":"Gish","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_100","first-page":"1469","article-title":"Phosphorylation-specific status of RNAi triggers in pharmacokinetic and biodistribution analyses","volume":"45","author":"Trubetskoy","year":"2017","journal-title":"Nucl. Acids Res."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Wooddell, C.I., Yuen, M.F., Chan, H.L., Gish, R.G., Locarnini, S.A., Chavez, D., Ferrari, C., Given, B.D., Hamilton, J., and Kanner, S.B. (2017). RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci. Transl. Med., 9.","DOI":"10.1126\/scitranslmed.aan0241"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/gtc.12437","article-title":"Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus","volume":"21","author":"Sakuma","year":"2016","journal-title":"Genes Cells"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","article-title":"Targeting hepatitis B virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication","volume":"118","author":"Dong","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1111\/febs.14094","article-title":"Virus-host interplay in hepatitis B virus infection and epigenetic treatment strategies","volume":"284","author":"Hensel","year":"2017","journal-title":"FEBS J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/mp\/sst075","article-title":"Zinc fingers, TAL effectors, or Cas9-based DNA binding proteins: what\u2019s best for targeting desired genome loci?","volume":"6","author":"Straubeta","year":"2013","journal-title":"Mol. Plant"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt1319","article-title":"An improved zinc-finger nuclease architecture for highly specific genome editing","volume":"25","author":"Miller","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nmeth.1539","article-title":"Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures","volume":"8","author":"Doyon","year":"2011","journal-title":"Nat. Methods"},{"key":"ref_109","first-page":"111","article-title":"Hepatitis B virus can be inhibited by DNA methyltransferase 3a via specific zinc-finger-induced methylation of the X promoter","volume":"79","author":"Xirong","year":"2014","journal-title":"Biochemistry"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/1087057112463066","article-title":"Creation of a six-fingered artificial transcription factor that represses the hepatitis B virus HBx gene integrated into a human hepatocellular carcinoma cell line","volume":"18","author":"Zhao","year":"2013","journal-title":"J. Biomol. Screening"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/10\/5\/357\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:50:38Z","timestamp":1760187038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/10\/5\/357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,9]]},"references-count":110,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5]]}},"alternative-id":["genes10050357"],"URL":"https:\/\/doi.org\/10.3390\/genes10050357","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,9]]}}}